NEW IMMUNOLOGICAL CHECKPOINTS FOR CANCER IMMUNOTHERAPY
Members of B7-CD28 family ligands and receptors play the important role in the co-stimulation and inhibition of the T-cell mediated immune response. Blocking of the B7 family molecules inhibiting the immune response (also called immunological checkpoints), CTLA4 and PD-1 / PD-L1 promoted to important therapeutic achievements in cancer immunotherapy and improved survival of cancer patient. The recent discovery of new B7 family molecules (such as B7-H3 [CD276], B7-H4 [B7S1 / B7x / Vtcn1], B7-H5 [VISTA / PD-1H / GI24], B7-H6 and B7-H7 [HHLA2]) has expanded therapeutic possibilities for the management of cancer patients. In this article, we discuss the clinical application of known blockers of immunological checkpoints and the prospects for the use of newly discovered molecules.